Karantas Ioannis D, Okur Mehmet E, Okur Neslihan Ü, Siafaka Panoraia I
Nicosia General Hospital, Nicosia, Cyprus.
University of Health Sciences, Faculty of Pharmacy, Department of Pharmacology, Istanbul, Turkey.
Endocr Metab Immune Disord Drug Targets. 2021;21(5):815-834. doi: 10.2174/1871530320666200810144004.
Cardiovascular diseases are the leading cause of death in the modern world and dyslipidemia is one of the major risk factors. The current therapeutic strategies for cardiovascular diseases involve the management of risk factors, especially dyslipidemia and hypertension. Recently, the updated guidelines of dyslipidemia management were presented, and the newest data were included in terms of diagnosis, imaging, and treatment. In this targeted literature review, the researchers presented the most recent evidence on dyslipidemia management by including the current therapeutic goals for it. In addition, the novel diagnostic tools based on theranostics are shown. Finally, the future perspectives on treatment based on novel drug delivery systems and their potential to be used in clinical trials were also analyzed. It should be noted that dyslipidemia management can be achieved by the strict lifestyle change, i.e., by adopting a healthy life, and choosing the most suitable medication. This review can help medical professionals as well as specialists of other sciences to update their knowledge on dyslipidemia management, which can lead to better therapeutic outcomes and newer drug developments.
心血管疾病是现代世界的主要死因，血脂异常是主要危险因素之一。当前心血管疾病的治疗策略包括对危险因素的管理，尤其是血脂异常和高血压。最近，血脂异常管理的更新指南发布，最新数据涵盖了诊断、影像学和治疗等方面。在这篇有针对性的文献综述中，研究人员通过纳入当前血脂异常的治疗目标，展示了血脂异常管理的最新证据。此外，还介绍了基于治疗诊断学的新型诊断工具。最后，还分析了基于新型药物递送系统的治疗未来前景及其用于临床试验的潜力。应当指出，通过严格改变生活方式，即采用健康的生活方式并选择最合适的药物，可以实现血脂异常的管理。这篇综述有助于医学专业人员以及其他学科的专家更新他们关于血脂异常管理的知识，从而带来更好的治疗效果和新的药物研发。
